Naphthyridine Derivatives Targeting Alpha v Beta 6 Integrin
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for pulmonary fibrosis and other fibrotic diseases lack effective pharmacological interventions, with existing therapies being ineffective in managing progressive fibrosis and associated respiratory failure, and there is a need for targeted therapies that can inhibit specific integrins to modulate TGFβ activation without exacerbating inflammation.
Innovation Solution
Development of pyrrolidine compounds that act as αvβ6 integrin antagonists, which are designed to inhibit the αvβ6 integrin, potentially inhibiting TGFβ activation and fibrosis progression, and are formulated into pharmaceutical compositions for therapeutic use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used for pulmonary fibrosis, then treatment is provided, but the therapies are ineffective in managing progressive fibrosis and respiratory failure
Solution Approach 1:
The patent applies parameter changes by developing compounds with specific molecular structures (formula I) that target the αvβ6 integrin pathway. The compounds feature variable substituents (R1-R6) that can be optimized to enhance binding affinity and selectivity for αvβ6 integrin, thereby improving therapeutic effectiveness while reducing harmful fibrotic effects through precise molecular parameter optimization.
Solution Approach 2:
The patent uses small molecule compounds as intermediaries that bind to αvβ6 integrin to modulate TGFβ activation. These compounds act as mediators between the integrin receptor and the TGFβ signaling pathway, providing targeted inhibition of fibrotic processes without directly interfering with inflammation pathways, thus resolving the contradiction between effectiveness and harmful side effects.
2Reliability
If broad-spectrum integrin antagonists are used, then TGFβ activation is inhibited, but inflammation may be exacerbated
Solution Approach 1:
The patent applies local quality by designing compounds with specific structural features (R1-R6 substituents) that confer selectivity for αvβ6 integrin over other integrin subtypes. This localized specificity ensures that TGFβ activation is inhibited through αvβ6 targeting while other integrin-mediated processes, including inflammatory pathways, remain unaffected, thus preventing inflammation exacerbation.
Solution Approach 2:
The patent optimizes selectivity parameters by varying molecular structure parameters (R1-R6 groups) to achieve high affinity for αvβ6 integrin while maintaining low affinity for other integrins. This parameter optimization enables selective inhibition of TGFβ activation without broad-spectrum integrin blockade, preventing harmful inflammatory effects.
Data Source
AI summary
A compound of formula (I) or a salt thereof wherein R1 represents a five-membered aromatic heterocycle selected from a N- or a C-linked mono- or di-substituted pyrazole, an N- or a C-linked optionally mono- or di-substituted triazole or an N- or a C-linked optionally mono-or di-substituted imidazole, which five-membered aromatic heterocycle may be substituted by one or two of the groups selected from a hydrogen atom, a methyl group, an ethyl group, a fluorine atom, a hydroxymethyl group, a 2-hydroxypropan-2-yl group, a trifluoromethyl group, a difluoromethyl group or a fluoromethyl group, except that when R1 represents an N-linked mono-or di-substituted pyrazole, R1 does not represent 3,5-Dimethyl-1H- pyrazol-1-yl, 5-Methyl-1H-pyrazol-1-yl, 5-Ethyl-3-methyl-1H-pyrazol-1-yl, 3,5-Diethyl-1H-pyrazol-1- yl, 4-Fluoro-3,5-dimethyl-1H-pyrazol-1-yl, 3-Methyl-1H- pyrazol-1-yl or 1H- pyrazol-1-yl.